Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers October 21, 2014
Pharmacy Choice - News - Front Page Healthcare News - October 21, 2014

Pharmacy News

 Front Page Healthcare News
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

10/21/14 - Ad Watch: Democrats use Obamacare against Ose [The Sacramento Bee]
Oct. 20 House Majority PAC, a Democratic group, has criticized Republican congressional challenger Doug Ose for his stances on veterans and Social Security. Following is text of the ad and an analysis by Christopher Cadelago of The Bee Capitol Bureau. Text: "Congressman Doug Ose says he has a new plan for health care.
10/21/14 - AMAG PHARMACEUTICALS INC. FILES (8-K) Disclosing Regulation FD Disclosure
On September 29, 2014, AMAG Pharmaceuticals, Inc. announced that it had entered into a definitive agreement to acquire the maternal health business of Lumara Health Inc.. In addition, based on the three months ended August 31, 2014, Lumara is on a run rate to achieve annualized net sales of approximately $188 million and adjusted EBITDA of approxim
10/21/14 - AnthroTronix Secures FDA Clearance for Brain Health Assessment Tool [Health & Beauty Close - Up]
"We are pleased that DANA has sought and received FDA clearance, leading the way for this type of game-changing technology," said Corinna Lathan, founder and CEO of AnthroTronix. "With the steady growth of the mHealth movement, technology that has evidence and science-based functionality is critical," said Duke University Medical Center's Murali D
10/21/14 - Aviro adds to growing m-health mix [ITWeb]
As Africa's mobile health ecosystem continues to grow in scale, Aviro a Cape Town- based technology start-up is focusing on improving the digital design of innovative health solutions. The company's Android app ART Treatment Mentor recently began a pilot project with nurses at Khayelitsha Hospital, adding a mobile dimension to their routine.
10/21/14 - BioSpecifics Tech. Reports FDA Approval Of SBLA For XIAFLEX
WASHINGTON- The U.S. Food and Drug Administration or FDA has approved the supplemental Biologics License Application or sBLA submitted by BioSpecifics Technologies Corp.' s partner, Auxilium Pharmaceuticals Inc., for XIAFLEX for the treatment of up to two Dupuytren's contracture cords in the same hand during a single treatment visit.
10/21/14 - BioSpecifics Technologies Corp. Announces FDA Approval of sBLA for XIAFLEX for the Concurrent Treatment of Two Dupuytren's Contracture Cords
BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX in the U.S. and XIAPEX in the EU, today announced that the U.S. Food and Drug Administration has approved the supplemental Biologics License Application submitted by BioSpecifics' partner, Auxilium...
10/21/14 - Blood Utilization Programs Could Improve Outcomes for Total Knee Arthroplasty
Blood utilization programs have the potential to improve outcomes and reduce costs among Medicare beneficiaries undergoing total knee arthroplasty, suggests a study published in the October 2014 Journal of Arthroplasty. Hospitals in the study with an above-average number of adverse events associated with TKA each spent an additional $105,000...
10/21/14 - Boston Scientific Receives FDA And CE Mark Approval For New CoverEdge? Surgical Leads For The Precision Spectra? Spinal Cord Stimulator (SCS) System
Boston Scientific Corporation has received U.S. Food and Drug Administration and CE Mark approval for the CoverEdge? 32 and CoverEdge? X 32 Surgical Leads, the world's first 32- contact surgical leads designed to blanket the spinal cord for unprecedented pain coverage. Boston Scientific is introducing the CoverEdge Surgical Leads at the Congr
10/21/14 - Boston Scientific's New Surgical Leads Receive FDA, CE Mark Approval
WASHINGTON- Boston Scientific Corp. Tuesday said its surgical leads- CoverEdge 32 and CoverEdge X 32- have received U.S. Food and Drug Administration approval as well as the CE Mark from European Union to provide software-guided stimulation to the spinal cord for relieving pain. The company said CoverEdge 32 and CoverEdge X were superior to existin
10/21/14 - Cardica Launches New Curved Tip Cartridge/reload To Microcutter XCHANGE 30 Surgical Stapler Product Line
Cardica, Inc. today announced the availability of the curved tip cartridge for its MicroCutter XCHANGE 30 surgical stapling device. Brendan C. Visser, assistant professor of surgery at the Stanford University Medical Center and Palo Alto Veterans Affairs Health Care Center. "We developed this important line extension for the MicroCutter surgi
10/21/14 - Cot Orphan Launches Mobile Application That Transforms Information Access To FDA and EMA Orphan Drug Status
Cot Orphan, LLC, the leader in orphan drug regulatory affairs, today announced the launch of OrphanDB, its first mobile app designed to provide industry leaders a single source of truth to all FDA and EMA orphan drug status through a simple search. Features include:? Granular search for orphan drugs matching criteria such as disease, active com
10/21/14 - Dignitana AB in meeting with the Food and Drug Administration (FDA)
Dignitana AB, a world leader in medical scalp-cooling technology for reducing hair loss related to chemotherapy, is pleased to announce that it has had a formal meeting with the Food and Drug Administration (FDA) in Washington D.C. The intention was to clarify a number of queries regarding the final clinical module. The meeting was held in a positi
10/21/14 - DNA Sequencing HPV Testing and Pap Smears Necessary for Optimum Patient Care, Noted Pathologist Reports in Oncology Journal, Cancers
By a News Reporter-Staff News Editor at Cancer Weekly Sin Hang Lee, M.D., a Milford Hospital pathologist and lead author of "From Human Papillomavirus Detection to Cervical Cancer Prevention in Clinical Practice," a medical-scientific paper published in Cancers, a quarterly oncology journal http://www.mdpi.com/2072-6694/6/4/2072, said that to pro
10/21/14 - FDA Accepts Lilly's NDA Filing For Empagliflozin/metformin Combination
INDIANAPOLIS- Eli Lilly and Co. Tuesday said the U.S. Food and Drug Administration or FDA has accepted its filing of New Drug Application or NDA for empagliflozin plus immediate-release metformin hydrochloride fixed-dose combination, which is an investigational compound being studied for the treatment of adults with type 2 diabetes or T2D.
10/21/14 - Findings from Cancer Hospital Has Provided New Information about Breast Cancer (Aberrant expression of CXCR4 significantly contributes to metastasis...
According to news reporting originating in Shantou, People's Republic of China, by NewsRx journalists, research stated, "Triple negative breast cancer is known for its visceral metastasis. Our news correspondents report that additional information may be obtained by contacting P. Yang, (C-W Du) Dept. of Breast Medical Oncology, Cancer Hospital of S
10/21/14 - Horizon Blue Cross Blue Shield of New Jersey Creates Ground-breaking Patient-centered Program for Cancer Treatment
Horizon Blue Cross Blue Shield of New Jersey announced today that it has joined with Regional Cancer Care Associates one of the nation's largest oncologist physician groups to create an Episode of Care program to deliver highly specialized care for breast cancer patients. The COTA platform also supports the effort to move from a fee-for-servi
10/21/14 - Humana and Riverside Medical Clinic Partner to Launch Value-Based Arrangement in California
Improved health and more coordinated care for Medicare Advantage members is the goal behind a new value-based arrangement and population health management partnership between Humana Inc. and Riverside Medical Clinic. As part of the partnership, Riverside Medical Clinic will open two new primary care practices in Riverside County under the Riverside
10/21/14 - IMBRUVICA (ibrutinib) Supplemental New Drug Application Submitted to the U.S. FDA for Waldenstrom's macroglobulinemia
Release date- 20102014- RARITAN, NJ- Janssen Research& Development, LLC today announced the submission of a supplemental New Drug Application for IMBRUVICA to the U.S. Food and Drug Administration by its strategic partner Pharmacyclics, Inc.. IMBRUVICA received FDA Breakthrough Therapy Designation in February 2013 for patients with WM and is being
10/21/14 - Iroko Pharmaceuticals Signs New Strategic Agreement With Landsteiner Scientific to Bring ZORVOLEX to Mexico
Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, today announced that its affiliate, Iroko Pharmaceuticals Inc., signed a licensing agreement with Landsteiner Scientific, S.A. de C.V., for the exclusive rights to market and sell ZORVOLEX capsules in Mexico. This additional
10/21/14 - J&J -IMBRUVICA (ibrutinib) Supplemental New Drug Application Submitted to the U.S. FDA for Waldenstrom's macroglobulinemia
Release date- 20102014- RARITAN, NJ,- Janssen Research& Development, LLC today announced the submission of a supplemental New Drug Application for IMBRUVICA to the U.S. Food and Drug Administration by its strategic partner Pharmacyclics, Inc.. IMBRUVICA received FDA Breakthrough Therapy Designation in February 2013 for patients with WM and is being
10/21/14 - Kaiser Permanente's Mail-Order Pharmacy Ranked Highest in Customer Satisfaction by J.D. Power for 6th Year in Row
For the 6 th consecutive year, Kaiser Permanente's mail-order pharmacy was ranked highest in customer satisfaction by the J.D. Power and Associates 2014 U.S. "We are dedicated to providing our members with high-quality health care that is convenient and affordable," said David Kvancz, vice president, national pharmacy programs and services, Kais
10/21/14 - Kentucky congressional candidates Barr, Jensen find little common ground during KET debate [Lexington Herald-Leader]
Andy Barr, R- Lexington, and Elisabeth Jensen, his Democratic challenger, laid out stark differences in their ideologies Monday night during a televised appearance on KET's Kentucky Tonight. Jensen told host Bill Goodman that she supported a proposed raise in the federal minimum wage to $10.10 an hour, the Affordable Care Act and the Dodd-Frank ban
10/21/14 - Local Ambulance Service Expresses Support for Quincy, WA Hospital One-Year Levy
The owner of Protection-1, which is the primary provider of Ambulance Services for Grant County Hospital District No. 2 is urging citizens in the greater Quincy, Washington area to strongly consider the importance of continuing to have an Emergency Room in Quincy, and as such to support the Hospital's one-year Proposition 1 Levy. Stated Brian Wil
10/21/14 - Magellan Health Selects HMS for National Fraud, Waste, and Abuse Services and Coordination of Benefit Solutions for Magellan Complete Care of Florida
HMS, a wholly owned subsidiary of HMS Holdings Corp., announced today that Magellan Health, Inc. has selected HMS for cost containment solutions, including fraud, waste, and abuse detection and prevention across the company, as well as for insurance verification and subrogation services for Magellan Complete Care of Florida, a Medicaid specialty pl
10/21/14 - Medical Imaging Technologies for Oncology Diagnostics Market: Global Industry Analysis and Forecast to 2020
Persistence Market Research is released new forthcoming report on title "Medical Imaging Technologies for Oncology Diagnostics Market: Global Industry Analysis and Forecast to 2020". New York, NY 10/21/2014 Medical imaging is a process of creation of high quality of image for the diagnosis of various diseases. Computed tomography includes mul
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2014 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

The Diversion of Controlled Substances and the Law
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comRxProHealth.comPharmacyPages.comNursingJobSource.comNurseZone.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415